Yet there is another, no less important, issue lurking beneath: firms like Arbutus stoke the hopes of millions, nurturing the belief that every disease will one day have a cure. It is a modern echo of humanity’s age-old yearning for immortality, as recounted in the Epic of Gilgamesh, where the hero is on a quest to find the plant of eternal life. Arbutus does not promise immortality—but in pledging a functional cure for HBV, it taps into that eternal, possibly futile, hope.
Verve Therapeutics (VERV), a US biotech firm, aims to transform cardiovascular care through gene editing. By altering liver DNA, it seeks to permanently lower LDL cholesterol—a key driver of heart disease. Unlike statins, which require lifelong use, Verve offers a one-off intervention. Early trials show LDL reductions of up to 55%, though the data remain preliminary. Regulatory and safety hurdles are considerable, and competition from giants like Amgen and Novartis is fierce. Yet optimism persists: on 16 June 2025, Verve’s shares nearly doubled on reports of a potential Eli Lilly takeover.
Yet therein lies another truth of radical innovation: transformative technologies often come with hefty price tags. When pharmaceutical giants acquire such breakthroughs, their initial benefits may be reserved for those wealthy enough to afford them.
Tech Startups: Revolutionary Tools or Vaporware?
Technological startups promising paradigm-shifting products may sidestep clinical trial risks, but that does not make them a safe bet. Even ostensibly ground-breaking technologies can fall flat in the marketplace—or be exposed as overhyped illusions. Unproven tech attracts both speculators and sceptics.
Consider Vuzix Corporation (VUZI), an American firm specialising in smart glasses and augmented reality (AR) eyewear for industry, healthcare, and consumers. These devices project information directly into the user’s field of vision—from maintenance manuals to surgical guidance. While the technology holds promise in logistics and telemedicine, AR adoption has been slower than anticipated.
Nano-X Imaging (NNOX) similarly claims to be reinventing medical imaging with a novel ‘cold cathode’ digital X-ray source. Its devices could cut costs by 90% and bring imaging to poorer regions. Yet short-seller reports, notably from Citron Research, have questioned the feasibility of the technology while pointing out the paucity of independent review.
Behind the shimmer of innovation lies a deeper philosophical risk. When startups peddle ‘revolutionary artefacts,’ they often intend not a transformation in human experience, but another gadget—a new screen in one’s periphery, another stream of real-time data. Technologies such as AR or digital imaging can enhance efficiency, improve access to care, and reduce costs. But they may also reshape our understanding of reality itself: what is not measured, visualised or digitised then increasingly ceases to be perceived as real.
Between Hope and Hype
The frenzy surrounding new technologies is not merely a reflection of faith in progress—it is a wager on the potential of human imagination, while any real-world application might be a far off prospect. From gene editing to cloud-connected scanners, these startups aspire to ambitions far loftier than their current financials might justify. Some are genuinely authoring the next chapter in the history of innovation. Others more closely resemble hack screenwriters for low-budget science fiction films.
History teaches caution. Technology, like capital, should not be taken at face value. In an age where DNA can be rewritten with the flick of a pipette and X-rays beamed via the cloud, the central question remains: which of these visionaries are truly reshaping the world—and which are merely staging it? It is in the murky space between hope and hype that the future is being forged—not only for technology, but for civilisation itself.
Statement
In an era drunk on innovation, small-cap firms like Arbutus, Verve, Vuzix, and Nano-X promise breakthroughs from gene editing to AR glasses. Their visions are grand, audacious and most of all, unfiltered. Yet there is something disquieting about biotech’s dream of immortality: are they curing disease or selling hope? Enhancing reality or monetising illusion? These firms trade not just in products, but in belief—belief that societal transformation is imminent, affordable, and benign.
